BENLYSTA (belimumab) injection

BENLYSTA is a prescription medicine used for the treatment of a type of nephritis (kidney inflammation) that’s caused by lupus. This condition is called lupus nephritis. Benlysta is used for lupus nephritis that’s active. If you have active lupus nephritis, it means you’re having symptoms of the disease. Brand Name: BENLYSTA (belimumab) injection, for subcutaneous use Initial U.S. Approval: 2011

Home | belimumab injection

BENLYSTA (belimumab) injection Price In India and Overseas
BENLYSTA (belimumab) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

BENLYSTA (belimumab) injection

Belimumab is used with other medications to treat certain types of systemic lupus erythematosus (SLE or lupus; an autoimmune disease in which the immune system attacks healthy parts of the body such as joints, skin, blood vessels, and organs) in adults and children 5 years of age and older.

BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated
for the treatment of:
• patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy;
• patients aged 5 years and older with active lupus nephritis who are receiving standard therapy.

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.

Drug (Brand / Generic): BENLYSTA / belimumab
Current Indications: systemic lupus erythematosus and lupus nephritis
Marketed by:: GlaxoSmithKline
Approval Date: 2011

Dosage forms and strengths of BENLYSTA (belimumab) injection
• Intravenous Infusion:
−For Injection: 120 mg or 400 mg of belimumab lyophilized powder in single-dose vial for reconstitution and dilution prior to intravenous infusion.
• Subcutaneous Injection:
−Injection: 200 mg/mL of belimumab in single-dose prefilled autoinjector or single-dose prefilled syringe.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.